Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis
Article first published online: 5 APR 2004
Copyright © 2004 by the American College of Rheumatology
Arthritis Care & Research
Volume 51, Issue 2, pages 278–283, 15 April 2004
How to Cite
Langford, C. A., Talar-Williams, C. and Sneller, M. C. (2004), Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis & Rheumatism, 51: 278–283. doi: 10.1002/art.20240
- Issue published online: 5 APR 2004
- Article first published online: 5 APR 2004
- Manuscript Accepted: 26 APR 2003
- Manuscript Received: 18 DEC 2002
- Wegener's granulomatosis;
- Mycophenolate mofetil;
- Remission maintenance
To examine the safety of mycophenolate mofetil (MMF) for remission maintenance in patients with Wegener's granulomatosis (WG) who had been treated with daily cyclophosphamide (CYC) and glucocorticoids to induce remission.
Fourteen patients were treated for active WG using a standardized regimen of CYC and glucocorticoids for induction of remission and MMF for remission maintenance. Outcome was assessed using predetermined definitions based on clinical characteristics and pathologic, laboratory, and radiographic findings.
Remission occurred in all 14 patients (100%) at a median time of 3 months. The median time to discontinuation of glucocorticoids was 8 months. No patients died during protocol treatment and 6 patients (43%) relapsed at a median of 10 months after achieving remission. MMF was well tolerated and no patients had to be withdrawn as a result of medication toxicity.
The use of CYC and glucocorticoids for induction of remission and MMF for remission maintenance was well tolerated, but disease relapses were observed.